Clinical data shows an average of 9 to 10% of starting body weight lost by the three-month mark on semaglutide
Chief Medical Officer, Kailera Therapeutics: Oral ribupatide shows a potentially game-changing clinical profile Kailera Therapeutics plans to initiate another Phase 2 oral study this year Chief of Clinical Development, Metabolic Diseases, Hengrui Pharma confirmed plans to advance into Phase 3 in China 5 Oral + injectable = portfolio hedge Kaileras lead injectable ribupatide (KAI-9531) already showed: 19.2% mean weight loss at 36 weeks (Phase 3, China) Comparable to @Eli Lilly and Companys Zepbound Oral ribupatide now adds access, convenience, and lifecycle flexibility
Shedding excess weight can significantly improve your quality of life in numerous ways: Now that you understand the cost factors and potential long-term benefits, the next step is to consult a qualified healthcare professional
This isnt just a prescription
Individual results vary based on health status, lifestyle, and treatment adherence